These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 27375444)

  • 1. DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
    Duchon A; Herault Y
    Front Behav Neurosci; 2016; 10():104. PubMed ID: 27375444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.
    Brault V; Nguyen TL; Flores-Gutiérrez J; Iacono G; Birling MC; Lalanne V; Meziane H; Manousopoulou A; Pavlovic G; Lindner L; Selloum M; Sorg T; Yu E; Garbis SD; Hérault Y
    PLoS Genet; 2021 Sep; 17(9):e1009777. PubMed ID: 34587162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.
    Feki A; Hibaoui Y
    Brain Sci; 2018 Oct; 8(10):. PubMed ID: 30332747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
    Çağlayan ES
    Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Atas-Ozcan H; Brault V; Duchon A; Herault Y
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
    Stringer M; Goodlett CR; Roper RJ
    Mol Genet Genomic Med; 2017 Sep; 5(5):451-465. PubMed ID: 28944229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
    Becker W; Soppa U; Tejedor FJ
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):26-33. PubMed ID: 24152332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
    Marechal D; Brault V; Leon A; Martin D; Lopes Pereira P; Loaëc N; Birling MC; Friocourt G; Blondel M; Herault Y
    Hum Mol Genet; 2019 May; 28(9):1561-1577. PubMed ID: 30649339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
    Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
    Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X
    Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome.
    Park J; Chung KC
    Exp Neurobiol; 2013 Dec; 22(4):244-8. PubMed ID: 24465139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome.
    Stensen W; Rothweiler U; Engh RA; Stasko MR; Bederman I; Costa ACS; Fugelli A; Svendsen JSM
    Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.
    Moreau M; Carmona-Iragui M; Altuna M; Dalzon L; Barroeta I; Vilaire M; Durand S; Fortea J; Rebillat AS; Janel N
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
    Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
    J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1A and cognition: A lifelong relationship.
    Arbones ML; Thomazeau A; Nakano-Kobayashi A; Hagiwara M; Delabar JM
    Pharmacol Ther; 2019 Feb; 194():199-221. PubMed ID: 30268771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DYRK1a Inhibitor Mediated Rescue of
    Zhu B; Parsons T; Stensen W; Mjøen Svendsen JS; Fugelli A; Hodge JJL
    Front Pharmacol; 2022; 13():881385. PubMed ID: 35928283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.
    De Toma I; Ortega M; Aloy P; Sabidó E; Dierssen M
    Front Mol Neurosci; 2019; 12():272. PubMed ID: 31803016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.